Arabic Arabic English English French French German German
dark

Valneva switches focus to bilateral discussions to supply its inactivated, adjuvanted COVID-19 vaccine candidate VLA2001

ValnevaValneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced it is now focusing on bilateral discussions, on a country by country basis, to supply its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001, and is consequently deprioritizing the ongoing centralized discussions with the European Commission (EC).

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Verona Pharma to Report First Quarter 2021 Financial Results and Provide Corporate Update

Next Post

Elevated Asthma Risk by Gut Microbiome Imbalance in Newborns

Related Posts
Total
0
Share